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The mechanisms linking hepatocellular death, he-
patic stellate cell (HSC) activation, and liver fibrosis
are largely unknown. Here, we investigate whether
acidic sphingomyelinase (ASMase), a known regula-
tor of death receptor and stress-induced hepatocyte
apoptosis, plays a role in liver fibrogenesis. We show
that selective stimulation of ASMase (up to sixfold),
but not neutral sphingomyelinase, occurs during the
transdifferentiation/activation of primary mouse HSCs
into myofibroblast-like cells, coinciding with cathepsin
B (CtsB) and D (CtsD) processing. ASMase inhibition or
genetic down-regulation by small interfering RNA
blunted CtsB/D processing, preventing the activation
and proliferation ofmouse andhumanHSCs (LX2 cells).
In accordance, HSCs from heterozygous ASMase mice
exhibited decreased CtsB/D processing, as well as lower
levels of -smooth muscle actin expression and prolif-
eration. Moreover, pharmacological CtsB inhibition
reproduced the antagonism of ASMase in preventing
the fibrogenic properties of HSCs, without affecting
ASMase activity. Interestingly, liver fibrosis induced
by bile duct ligation or carbon tetrachloride adminis-
tration was reduced in heterozygous ASMase mice
compared with that in wild-type animals, regardless
of their sensitivity to liver injury in either model. To
provide further evidence for the ASMase-CtsB path-
way in hepatic fibrosis, liver samples from patients
with nonalcoholic steatohepatitis were studied. CtsB
and ASMase mRNA levels increased eight- and three-
fold, respectively, in patients compared with healthy
controls. These findings illustrate a novel role of
ASMase in HSC biology and liver fibrogenesis by regu-
lating its downstream effectors CtsB/D. (Am J Pathol
2010, 177:1214–1224; DOI: 10.2353/ajpath.2010.091257)
Hepatic fibrosis is a wound-healing response of the liver
to chronic injury and represents a common and complex
clinical challenge worldwide.1–3 Liver fibrosis often re-
flects progressive liver disease caused by a variety of
factors and etiologies including viral infection, cholesta-
sis, alcoholic steatohepatitis, and nonalcoholic steato-
hepatitis (NASH). In developed countries, nonalcoholic
fatty liver disease is associated with increasing rates of
obesity and is currently one of the most common forms of
chronic liver disease and a major cause of hepatic fibro-
sis. Nonalcoholic fatty liver disease, which encompasses
a spectrum of liver diseases ranging from simple steato-
sis to NASH, is characterized by oxidative stress, inflam-
mation, hepatocellular death, and fibrosis, which can
further progress to cirrhosis and hepatocellular carci-
noma.4–6 Thus, the number of individuals at risk for fibrosis
and end-stage liver disease is rapidly expanding.7
In the liver, myofibroblasts are potentially derived from
a number of cellular sources including activated hepatic
stellate cells (HSCs), which mediate the fibrotic compo-
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nent of the wound-healing response to chronic injury.1,2,8
Under these conditions, HSCs undergo a phenotypic
transformation from quiescent, nonproliferating, retinoid-
storing cells, to a proliferating, matrix-producing phenotype
similar to myofibroblasts responsible for the progression of
liver fibrosis.9,10 Despite increasing knowledge of themech-
anisms that govern this so-called “activation,” the treatment
for advanced liver fibrosis is inefficient, and hence the de-
velopment of novel antifibrotic targets and therapies is
essential.
Membrane sphingolipids have been implicated in sig-
nal transduction cascades regulating proliferation, differ-
entiation, and cell death.11,12 Among sphingolipids, cer-
amide has attracted considerable attention, given its
central role in sphingolipid metabolism. Cellular cer-
amide levels increase in response to a variety of stimuli
and agents from chemotherapy13 to death ligands,14–17
radiation,18 or viral/bacterial infections,19,20 because of
the hydrolysis of sphingomyelin mainly by two specific
phosphodiesterases named sphingomyelinases, a plasma
membrane-bound neutral sphingomyelinase (NSMase)
and an acidic SMase (ASMase).21–24 In particular,
ASMase is expressed by almost any cell type and is
mainly located at the endosomal/lysosomal compart-
ment, although it has also been found at the plasma
membrane in specific microdomains, where it serves as a
signaling platform by cell surface receptors such as
Fas.14–17 The placement of ASMase at the crossroad of
vesicular trafficking and cellular signaling suggests that
ASMase exerts important functions in signal transduction
pathways. For instance, tumor necrosis factor (TNF) is a
prominent prototype of an ASMase-activating cytokine
that is central to the regulation of both the innate and the
adaptive immune system as well as cell death.25,26 Al-
though ASMase has been recognized to play a key role in
the pathophysiology of different common diseases,27 its
specific contribution to liver fibrosis has not been exam-
ined previously.
Moreover, the participation of cathepsin D (CtsD) as a
target of ASMase-generated ceramide in endolysosomal
compartments28,29 and the observation that cathepsin B
(CtsB)-deficient hepatocytes are resistant to TNF-depen-
dent cell death30 imply a functional relationship between
ASMase and cathepsins, at least, in cell death regulation.
However, this specific link has not been previously ad-
dressed in HSC biology and liver fibrosis. Because we
have just uncovered a new function of CtsB and CtsD in
mediating HSC activation and liver fibrosis,31 our aim was
to investigate the role of ASMase in hepatic fibrogenesis.
In this study, we tested whether ASMase contributes to
the activation of mouse HSCs in vitro and to the develop-
ment of fibrosis in vivo after bile duct ligation (BDL) or
chronic carbon tetrachloride (CCl4) injection. Here, we
show that ASMase activity is induced during the transdif-
ferentiation of HSCs into myofibroblasts, whereas HSC
activation and proliferation are reduced by genetic or
pharmacological antagonism of ASMase. Interestingly,
heterozygous ASMase mice were resistant to BDL and
chronic CCl4 administration-induced liver fibrosis com-
pared with wild-type mice, even though their sensitivity to
liver injury was markedly different with reduced liver
damage in ASMase/ mice after BDL but not after
CCl4 administration. In addition, patients with NASH
displayed enhanced levels of both CtsB and ASMase
mRNA, underscoring the role of the ASMase-cathep-
sins axis in liver pathology and its relevance for future
therapeutic approaches.
Materials and Methods
Reagents
The following reagents were from Invitrogen (Paisley,
UK): Dulbecco’s modified Eagle’s medium, trypsin-
EDTA, penicillin-streptomycin, TRIzol, fetal bovine serum,
HistoGrip, Opti-MEM, and Lipofectamine LTX with PLUS.
All tissue culture ware was from Nunc (Roskilde, Den-
mark). The DAKO Biotin Blocking System, peroxidase
substrate (diaminobenzidine), peroxidase buffer, and he-
matoxylin were from DAKO (Glostrup, Denmark). Aqua-
tex was from Merck (Darmstadt, Germany). The ABC kit
was from Vectastain (Burlingame, CA). Platelet-derived
growth factor (PDGF)-BB was from PeproTech EC (Lon-
don, UK). Proteinase inhibitors were from Roche (Madrid,
Spain). The iScript One-Step RT-PCR kit with SYBR
Green was from Bio-Rad (Hercules, CA). ECL Western
Blotting Substrate was from Pierce (Thermo Fisher Sci-
entific, Rockford, IL). Imipramine, amitriptyline, and
Ca074Me were from Sigma-Aldrich (St. Louis, MO), and
unless otherwise stated all other reagents were also from
Sigma-Aldrich.
Antibodies
We used the following primary antibodies: rabbit poly-
clonal anti-cathepsin B from Upstate (Millipore, Billerica,
MA), goat polyclonal anti-cathepsin D from Santa Cruz
Biotechnology (Heidelberg, Germany), and monoclonal
antibodies anti--smooth muscle actin (SMA) and anti--
actin from Sigma-Aldrich. Rabbit polyclonal anti--SMA
and rabbit polyclonal anti-myeloperoxidase were from
Abcam (Cambridge, UK). ECL-labeled anti-mouse, anti-
rabbit, and anti-goat antibodies were from Sigma-Aldrich.
Mice and HSC Isolation
Wild-type, heterozygous, and ASMase knockout mice
(male, 8 to 10 weeks old, littermates) (C57BL/6 strain)
were obtained by propagation of heterozygous breeding
pairs (a generous gift from R. Kolesnick, Memorial Sloan-
Kettering Cancer Center, New York, NY, and E. Gulbins,
University of Duisburg-Essen, Essen, Germany) and
genotyped as described previously.26 All animals re-
ceived humane care according to the criteria outlined in
the Guide for the Care and Use of Laboratory Animals, pub-
lished by the National Institutes of Health.32 HSCs were
isolated by perfusion with collagenase-pronase and cul-
tured as described previously.31 Cells were cultured in
Dulbecco’s modified Eagle’s medium complemented
with 10% fetal bovine serum and antibiotics at 37°C in a
humidified atmosphere of 95% air and 5% CO2.
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To perform BDL, ASMase/ and ASMase/ mice were
anesthetized by isoflurane inhalation. Under anesthesia,
the peritoneal cavity was opened and the common bile
duct was double-ligated with 5-0 sutures and cut be-
tween the ligatures. Controls underwent a sham opera-
tion that consisted of exposure but not ligation of the
common bile duct. Animals were sacrificed 4 days after
BDL, and liver and serum samples were collected for
analyses. In another set of experiments, ASMase/ and
ASMase/ mice were treated with CCl4 diluted in corn
oil at a dose of 0.5 l of CCl4/g b.wt. by intraperitoneal
injection twice a week, for 6 weeks. Control animals re-
ceived vehicle alone.
In Vitro Small Interfering RNA Transfection
To silence ASMase expression, specific predesigned
siRNAs for mouse33 were used for transfection using
Lipofectamine LTX with PLUS following the manufacture’s
instruction as described previously.31 Cells were trans-
fected 5 days after isolation and usually assayed 48
hours after small interfering (si) RNAs transfection.
ASMase and NSMase Activities
ASMase and NSMase activities from tissue or HSC ly-
sates were determined using a fluorescent sphingomye-
lin analog (NBD-C6-sphingomyelin). Samples were incu-
bated for 60 minutes at 37°C in incubation buffer containing
10 mol/L NBD-C6-sphingomyelin (250 mmol/L sodium ac-
etate and 0.1% Triton X-100, pH:5.0, for ASMase analysis,
and 20 mmol/L HEPES, 1 mmol/L MgCl2, and 0.1% Triton
X-100, pH 7.4, for NSMase). Lipids were extracted, dried
under N2, and separated by thin-layer chromatography
(chloroform-methanol-20% NH4OH, 70:30:5, v/v). NBD-
ceramide was visualized under UV light, and images
were acquired and analyzed using a Gel Doc XR System
with Quantity One software (Bio-Rad).
Real Time RT-PCR and Primer Sequences
Total RNA from HSCs, mouse liver tissues, or LX2 cells was
isolated with TRIzol reagent. Real-time RT-PCR was per-
formed with an iScript One-Step RT-PCR Kit with SYBR
Green following the manufacturer’s instructions. The prim-
ers sequences used were the following: mouse -SMA,
forward 5-ACTACTGCCGAGCGTGAGAT-3 and reverse
5-AAGGTAGACAGCGAAGCCAA-3 (GenBank accession
no. NM_007392); mouse transforming growth factor-, for-
ward 5-GTCAGACATTCGGGAAGCAG-3 and reverse 5-
GCGTATCAGTGGGGGTCA-3 (GenBank accession no.
NM_011577); mouse -actin, forward 5-GACGGCCAGGT-
CATCACTAT-3and reverse 5-CGGATGTCAACGTCA-
CACTT-3 (GenBank accession no. NM_007393); mouse
collagen type 11 (Col1A1), forward 5-ACTTCAGCTTCCT-
GCCTCAG-3 and reverse 5-TGACTCAGGCTCTT-
GAGGGT-3 (GenBank accession no. NM_007742); mouse
TNF-, forward 5-CTGAACTTCGGGGTGATCGGT-3 and
reverse 5-ACGTGGGCTACAGGCTTGTCA-3 (GenBank
accession no. NM_013693); mouse 2,5 oligoadenylate
synthetase 1, forward 5-GACCTGCTGAAGGAGGTGAA-3
and reverse 5-GGTACGCCCACTGATGAGAT-3 (Gen-
Bank accession no. AF466822); human -actin, forward
5-GATGAGATTGGCATGGCTTT-3 and reverse 5-
GAGAAGTGGGGTGGCTT-3 (GenBank accession no.
NM_001101); and human -SMA, forward 5-CCGAC-
CGAATGCAGAAGG-3 and reverse 5-ACAGAGTATTT-
GCGCTCCGGA-3 (GenBank accession no. NM_001613).
CtsB Activity
CtsB activity was assayed fluorimetrically with Z-Arg-Arg-
7-amido-4-methylcoumarin hydrochloride (60 mol/L) at
pH 7.4 and 37°C as described previously.31
[3H]Thymidine Incorporation
Proliferation was estimated as the amount of [3H]thymi-
dine incorporated into trichloroacetic acid-precipitable
material as described previously.31
SDS-Polyacrylamide Gel Electrophoresis and
Immunoblot Analysis
Lysates were prepared in radioimmunoprecipitation as-
say buffer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl,
1% Nonidet P-40, 1 mmol/L Na3VO4, 1 mmol/L EDTA,
0.25% sodium deoxycholate, 0.1% SDS, and 1% Triton
X-100 plus proteinase inhibitors). Protein concentration
was determined by the Bradford assay, and samples
containing 10 to 30 g were separated by 8 to 10%
SDS-polyacrylamide gel electrophoresis. Proteins were
transferred to nitrocellulose membranes. After mem-
branes were blocked in 8% nonfat milk in 20 mmol/L
Tris-HCl, 150 mmol/L NaCl, and 1% Tween 20 for 1 hour
at room temperature, the membranes were incubated
with the primary antibody overnight and developed with
the ECL-peroxidase system.
Determination of Hydroxyproline in Liver Tissue
Hepatic hydroxyproline content was determined as de-
scribed by Jamall et al.34 In brief, tissue samples were
hydrolyzed in 6 mol/L HCl overnight at 100°C and purified
4-hydroxy-L-proline standards for 20 minutes at 120°C.
Free hydroxyproline content from each hydrolysate was
oxidized with Chloramine-T. The addition of Ehrlich re-
agent resulted in the formation of a chromophore that was
read at 550 nm. Data were normalized to liver wet weight.
Immunohistochemical Staining
Paraffin molds containing liver sections were cut into
5-m sections and mounted on HistoGrip-coated slides.
The sections were deparaffinized in xylene and dehy-
drated in a graded alcohol series. When necessary, en-
dogenous peroxidase (3% H2O2) and endogenous avidin
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and biotin were blocked. Slides were incubated with
primary antibody overnight in a wet chamber at 4°C. After
a rinse with 1 PBS, the slides were incubated with a
biotinylated antibody for 45 minutes in a wet chamber
and developed with an ABC Kit with peroxidase substrate
(diaminobenzidine) and peroxidase buffer. After the
slides were rinsed with tap water, they were counter-
stained with hematoxylin and mounted with Aquatex.
H&E and Sirius Red Staining
Livers were fixed, and sections of 7-m were routinely
stained with H&E or with a 0.1% Sirius Red-picric solution
following standard procedures. Bile-infarcted areas (the
percentage of infarct area per high power field) were also
quantified using digital image analysis software (ImageJ).
Human NASH Cohort
Patients with either borderline NASH (n  14) or definite
NASH (n  18), according to the Kleiner classification,35
sent to the hospital for bariatric surgery were included in
the study. Patients underwent gastric bypass by laparos-
copy and during the surgery procedure a liver biopsy
was obtained using a Tru-Cut needle. Normal livers were
obtained from optimal cadaveric liver donors (n  3) or
resection of liver metastases (n  2). All controls had
normal serum aminotransferase levels and normal liver
histology. These subjects did not have a past history of
liver disease, alcohol abuse, or metabolic syndrome. The
study was approved by the ethics committee of the Hos-
pital Clinic, and all patients gave informed consent.
Hepatic Gene Expression Analysis in Human
Samples
Liver biopsy specimens were submerged in an RNA sta-
bilization solution (RNAlater, Ambion, Applied Biosys-
tems, Austin, TX) and stored at 20°C until RNA extrac-
tion. Total RNA was extracted with TRIzol. Five hundred
micrograms of total RNA were retrotranscribed with a
high-capacity complementary DNA Archive Kit (Applied
Biosystems). The genes selected were distributed into
384-well TaqMan Low Density Array cards, and samples
were analyzed in quadruplicate using an ABI PRISM
7900 (Applied Biosystems). Predesigned TaqMan as-
says for target genes from Applied Biosystems were
used (CtsB, Hs00157194_m1; ASMase, Hs00609415_
m1; and 18S, Hs99999901_s1). Expression levels of tar-
get genes were normalized to expression of 18S rRNA
(endogenous gene). Gene expression values were cal-
culated based on the Ct method.
36 The results are
expressed as 2Ct referred as fold in relation to mean
normal livers.
Statistical Analysis
All images display representative data from at least three
independent observations. Statistical analyses were per-
formed using Microsoft Excel software. The statistical
significance of differences was determined using the
unpaired, nonparametric Student’s t-test.
Results
In Vitro Activation of Mouse Primary HSCs
Parallels ASMase Stimulation
The culture of primary freshly isolated HSCs on plastic is
known to cause transdifferentiation from a quiescent to a
proliferating phenotype characterized by the activation of
matrix-producing genes, which is the standard approach
to analyze the activation of HSCs into myofibroblast-like
cells.2,8,9 Because this transdifferentiation is a central
event in liver fibrogenesis, we first studied whether this
process is accompanied by changes in ASMase activity.
Thus, freshly prepared mouse primary HSCs were iso-
lated to analyze ASMase and NSMase activity at different
time points during transdifferentiation in culture. As shown in
Figure 1A, ASMase activity, but not NSMase activity, in-
creased more than fivefold from day 2 to day 9 of culture. In
addition, the ASMase activity observed in primary mouse
HSCs at day 9 was similar to the ASMase activity of LX2
cells (620  85 vs. 583  63 arbitrary units/mg of pro-
tein), an immortalized human HSC cell line similar to
human activated HSCs.37 This increase in ASMase activ-
ity paralleled the expression of -SMA, a reliable marker
of the phenotypic transformation of HSCs into myofibro-
blast-like cells,2 which coincided with the levels of mature
forms of CtsB and CtsD (Figure 1B). Thus, these findings
indicate that in vitro activation of HSCs results in marked
and selective stimulation of ASMase.
Figure 1. ASMase activity increases concordantly with CtsB and CtsD expres-
sion during HSC activation. A: Time-course of ASMase and NSMase activity
during mouse HSC activation in culture. B: Time-course of -SMA, CtsB, and
CtsD expression in primary mouse HSCs in in vitro culture from day two to day
nine. Data are means  SD; n  3. *P  0.05 versus day 2 HSCs.
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Pharmacological ASMase Inhibition or Genetic
Silencing Blunts CtsB/D Processing and HSC
Activation
Given our previous results positioning CtsB/D as key
players in liver fibrosis31 and because a functional rela-
tionship between ASMase and cathepsins has been es-
tablished only in cell death regulation,28,29 we decided to
evaluate whether the increased processing of CtsB
and/or CtsD observed during HSC activation and re-
cently associated with liver fibrogenesis,31 was depen-
dent on ASMase. Therefore, ASMase was antagonized
by two approaches, pharmacological inhibition and ge-
netic down-regulation by siRNAs. Imipramine and ami-
triptyline are weak bases that induce the detachment of
ASMase from the intralysosomal membrane, resulting in
its subsequent functional inactivation.38 As shown in Fig-
ure 2A, both imipramine treatment and ASMase silencing
by siRNA resulted in a reduction in ASMase activity by
85  4 and 48  12%, respectively, without inducing an
interferon response (not shown). The decline in ASMase
activity, either by pharmacological inhibition or genetic
silencing, resulted in decreased expression of CtsB/D
processed forms (Figure 2, B and C). Moreover, the
expression of -SMA was also reduced under these con-
ditions (Figure 2, B and D), indicating an attenuation of
the fibrogenic properties of HSCs after ASMase antago-
nism. The expression of Col1A1 or transforming growth
factor-, however, was not significantly altered after
ASMase inhibition or silencing (not shown), discarding
the theory of direct participation of ASMase in either of
these two pathways. On the other hand, complete CtsB
inhibition, using Ca074Me, was able to significantly de-
crease transforming growth factor- expression (not
shown), consistent with our previous observations.31 In
addition, pharmacological inhibition of ASMase dramati-
cally prevented HSC proliferation (Figure 2E). Even
though cathepsins have previously been implicated in
the degradation of PDGFR,39,40 we have not observed
any alteration in the basal levels of PDGFR with inhibi-
tion of either ASMase or CstB (not shown). In line with this
result, we have previously reported that although CtsB
inhibition did not affect PDGFR levels, it impaired AKT
phosphorylation after PDGF challenge, thus regulating
HSC proliferation.31 To analyze the hierarchy between
ASMase and cathepsins, we evaluated the effect of CtsB
inhibition on ASMase levels. CtsB inhibition did not alter
ASMase activity (Figure 2F) but was able to significantly
blunt HSC proliferation (Figure 2E). Therefore, our results
suggest that CtsB and CtsD processing depend on and
are downstream of ASMase during the activation of HSCs
into myofibroblasts.
ASMase Inhibition Attenuates the Proliferation of
Human HSCs
To examine the relevance of the preceding findings in hu-
man fibrogenesis, we also evaluated the effect of ASMase
inhibition in the human LX2 cell line.37 As shown in Figure
3A, ASMase inhibition by either imipramine or amitriptyline
down-regulated the processing of CtsB and CtsD forms
(Figure 3B), resulting in a striking decrease of -SMA ex-
pression at the protein and mRNA levels (Figure 3, B and
Figure 2. ASMase inhibition or siRNA transfection reduces HSC activation and
proliferation. A: ASMase activity after inhibition with imipramine (Imip, 25
mol/L) for 24 hours or ASMase siRNA silencing for 48 hours, in cultured 7-days
old mouse HSCs. CtsB and CtsD protein expression (B) and -SMAmRNA levels
(D) after ASMase siRNA silencing for 48 hours, in cultured 7-days old mouse
HSCs. C: Time course of CtsB, CtsD, and -SMA expression after ASMase
inhibition (Imip, 25 mol/L) in 7-day-old HSCs. E: Time course of HSC prolif-
eration in the presence of ASMase (Imip, 25mol/L) or CtsB inhibitor (Ca074Me,
10 mol/L) in 7-day-old HSCs. F: ASMase and CtsB activity on inhibition of CtsB
with Ca074Me (10 mol/L, 24 hours) in 7-day-old HSCs. Data are means  SD;
n  4. *P  0.05 versus control HSCs. Ctrl, control.
Figure 3. ASMase inhibition decreases CtsB, CtsD, and -SMA expression as
well as proliferation in the human LX2 cell line. A: ASMase activity after
inhibition with imipramine (Imip, 25 mol/L) or amitriptyline (Ami, 25
mol/L) for 24 hours in LX2 cells. CtsB, CtsD, and -SMA protein expression
(B) and -SMA mRNA levels (C) in LX2 cells after ASMase inhibition with
imipramine (25 mol/L) or amitriptyline (25 mol/L) for 24 hours. D: Time
course of HSC proliferation in LX2 cells in the presence ASMase inhibitors
(imipramine, 25 mol/L; amitriptyline, 25 mol/L) for up to 72 hours. Data
are means  SD; n  3. *P  0.05 versus control LX2 cells. Ctrl, control.
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C), followed by a reduction in LX2 proliferation (Figure 3D).
Thus, in humans and rodents, the regulation of HSC activa-
tion and proliferation by ASMase-mediated CtsB/D pro-
cessing may be of potential relevance in liver fibrosis.
HSCs from Heterozygous ASMase Mice
Exhibit Decreased ASMase Activity, CtsB/D
Processing, and Proliferation
Because pharmacological inhibition or siRNA-mediated
reduction in ASMase expression decreased CtsB/D lev-
els and HSC proliferation, we next evaluated the in vivo
transdifferentiation process using HSCs from mice with a
genetic reduction in ASMase. Indeed, HSCs from het-
erozygous ASMase mice displayed a 60 to 70% de-
crease in ASMase activity (Figure 4A). ASMase/ HSCs
exhibited low CtsB/CtsD and -SMA expression during in
vitro activation (Figure 4B) compared with wild-type
HSCs, consistent with the preceding data on ASMase
antagonism (either pharmacological or by siRNA down-
regulation). Of note, the normal proliferation rate of het-
erozygous ASMase/ HSCs was slower than that of
wild-type HSCs (Figure 4C). Moreover, CtsB inhibition,
using the specific CtsB inhibitor Ca074Me, down-regu-
lated both the proliferation (Figure 4C) and activation
(Figure 4D) of wild-type and heterozygous ASMase
HSCs. These findings further strengthened the evidence
for a role of ASMase in the regulation of CtsB/D process-
ing, which is critical for HSC activation and proliferation.
Decreased Liver Damage and Fibrosis in
Heterozygous ASMase After Bile Duct Ligation
In view of the earlier findings indicating reduced fibrogenic
potential of HSCs from heterozygous ASMase mice, we
next assessed the in vivo susceptibility of wild-type and
heterozygous ASMase mice to liver fibrosis. BDL is a well
established model of liver fibrosis that is associated with
intrahepatic cholestasis and bile acid accumulation. Be-
cause cholestasis is also known to induce hepatocyte dam-
age, we used BDL in ASMase/ mice to examine the
contribution of ASMase in BDL-mediated hepatic damage,
HSC activation, and liver fibrosis. Based on our preceding
findings, we would expect lower liver fibrosis after BDL in
heterozygous ASMase mice compared with wild-type mice.
However, for liver or hepatocyte damage, the anticipated
effect of BDL on hepatocyte injury remained less predict-
able, based on recent findings reporting a critical role for
Kupffer cell-derived ASMase in AKT activation of hepato-
cytes that is required for the survival and regenerative re-
sponses after BDL.41
Total hepatic extracts from heterozygous ASMase
mice displayed a significant reduction in ASMase activity
(50 to 60% decrease) compared with wild-type livers, in
line with our observations during in vitro HSC activation
(Figure 4A). Serum alanine aminotransferase (ALT), as an
indicator of liver damage, was markedly increased in
wild-type mice after BDL for 4 days. However, unexpect-
edly, ALT levels were significantly reduced in heterozy-
gous ASMase BDL mice compared with wild-type BDL
mice (Figure 5A). These observations were further vali-
dated by terminal deoxynucleotidyl transferase dUTP
nick-end labeling staining of liver sections, revealing se-
vere parenchymal damage after BDL in wild-type but not
in heterozygous ASMase livers (Supplemental Figure 1,
see http://ajp.amjpathol.org), thus indicating a novel role
for ASMase in cholestasis-induced hepatocellular death.
To analyze the fibrogenic process, levels of hydroxypro-
line (Figure 5B), a major component of collagen, and
Col1A1 mRNA (Figure 5C) were analyzed. Both parame-
ters were significantly enhanced in wild-type BDL livers
but reduced in heterozygous ASMase BDL livers. Bile
infarcts are confluent foci of degenerated hepatocytes
due to bile acid toxicity and are a prominent feature of
liver injury in the BDL mouse. The number of bile infarcts
in the liver was quantified by conventional H&E staining.
Numerous bile infarcts per high power field area were
observed in the wild-type BDL model; however, the oc-
currence of bile infarcts was scarce in heterozygous BDL
livers (Figure 5D). Histopathological examination of liver
tissue (Figure 5E) demonstrated cholestatic hepatitis,
with widespread incidence of bile infarcts and hepato-
cellular damage in wild-type BDL mice. In contrast, het-
erozygous ASMase mice displayed minor liver injury.
Moreover, when the appearance of collagen was ana-
lyzed by Sirius Red staining, the presence of collagen
fibers was only observed in wild-type BDL mice but not in
ASMase/ mice (Figure 5E). This enhanced liver dam-
age and the presence of bile infarcts in wild-type BDL
mice occurred despite expression of TNF in heterozy-
Figure 4. Heterozygous ASMase/ HSCs exhibit decreased expression of
CtsB, CtsD, and -SMA, and reduced proliferation in culture. A: ASMase
activity in cultured 7-day-old wild-type or heterozygous ASMase/ HSCs. B:
Time course of CtsB, CtsD, and -SMA protein expression in wild-type and
heterozygous ASMase/ HSCs. Proliferation rate (C) and -SMA protein
levels (D) after CtsB inhibition (Ca074Me, 10 mol/L, 24 hours) in wild-type
or heterozygous ASMase/ 7-day-old HSCs. In A data are means  SD; n 
4. *P  0.01 versus ASMase/ HSCs. In C data are means SD; n 3. *P 
0.05 versus ASMase/ control HSCs; **P  0.05 versus respective controls
(Ctrl). Rel Unit, relative units.
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gous ASMase BDL mice similar to that in wild-type mice
(Figure 5F). Moreover, the total pool of bile acids in liver
extracts after BDL did not differ between wild-type and
heterozygous ASMase (not shown), indicating that the
reduction in liver fibrosis is not a consequence of lower
cholestasis. These findings underscore the relevance of
ASMase expression in controlling both hepatocellular
damage and liver fibrosis in mice during cholestasis.
Similar Liver Damage but Reduced Fibrosis
in Heterozygous ASMase Mice after CCl4
Administration
We next assessed the contribution of ASMase in an exper-
imental model that includes significant hepatocellular injury
followed by fibrosis, using the in vivo model of CCl4 admin-
istration, a well established model of liver injury and liver
fibrosis. CCl4 administered twice a week for 6 weeks to
ASMase/ and ASMase/ mice increased serum ALT to
a similar level in wild-type and heterozygous ASMase mice
(Figure 6A). Hepatocellular damage was also assessed by
terminal deoxynucleotidyl transferase dUTP nick-end label-
ing staining of liver sections, revealing comparable injury in
wild-type and ASMase/ livers (Supplemental Figure 1,
see http://ajp.amjpathol.org). However, regardless of the ex-
tent of liver damage, ASMase/ mice exhibited signifi-
cantly decreased liver fibrosis, detected by hydroxyproline
levels (Figure 6B), Col1A1 mRNA expression (Figure 6C),
immunostaining of -SMA-positive cells (Figure 6D), and
Sirius Red staining (Figure 6E). Thus, unlike the BDL model,
these findings underscore a hepatocellular damage-inde-
pendent role of ASMase in liver fibrosis.
Increased Expression of ASMase and CtsB in
Livers from Patients with NASH
Finally, to explore whether the observed effects in HSCs
and mice may be of potential relevance in human dis-
ease, we analyzed the mRNA expression of ASMase and
CtsB in patients with NASH at different stages. As shown
in Figure 7A, ASMase mRNA expression was significantly
increased in a group of 18 patients with NASH with a
Kleiner score of 5 to 6, indicative of definitive NASH35
based on the assessment of the range of histological
features of human NASH. However, in patients with a
score of 3 to 4 and classified as having borderline NASH
Figure 5. ASMase/ mice display decreased
liver damage and fibrosis compared with wild-type
mice when subjected to BDL. Serum ALT (A),
hydroxyproline levels (B), Col1A1 mRNA expres-
sion (C), percentage of bile infarcted area per high
power field (HPF) (D), H&E and Sirius Red stain-
ing of liver samples (E), and TNF mRNA expres-
sion levels (F) were determined 4 days after BDL
in ASMase/ and ASMase/; n  5 animals per
group. In A, B, C, and F, *P  0.05 versus sham
mice. In A, B, C, and D, **P  0.05 versus
ASMase/ BDL mice.
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(n  14), mean mRNA expression of ASMase was in-
creased compared with that of control patients, but it did
not reach statistical significance. Of note, both groups of
patients with NASH exhibited significantly enhanced
CtsB mRNA expression, with a higher mean value ob-
served in those patients who were classified as having
definitive NASH (Figure 7B). In addition, although labo-
ratory test abnormalities may be suggestive of NASH,
histological evaluation remains the only way to accurately
stage NASH. Even though the Kleiner activity score does
not include histological evaluation of fibrosis, 71% (10 of
14) and 91.44% (17 of 18) of our patients with borderline
or definite NASH, respectively, had some degree of he-
patic fibrosis, none of them reaching the cirrhosis stage.
Moreover, the presence of fibrosis is an unequivocal
indicator of progressive liver disease. In fact, despite the
classification established by our pathologists, the clinical
data of the patients with borderline or definite NASH,
summarized in Table 1, did not reveal major significant
differences among groups. In all, our findings indicate
that the elevation of ASMase and CtsB levels may be of
relevance in patients with NASH, including those at an
initial stage of the disease. As a caveat, the only informa-
tion we have available regarding CtsB and ASMase in
these sets of patients is their mRNA expression, and
hence we cannot directly determine that this mRNA in-
crease is exclusively due to fibrosis. Other features of
NASH, such as hepatocellular apoptosis, could contrib-
ute to this outcome because both CtsB and ASMase have
also been associated with apoptosis.12,25,27,29,30 More-
over, although in the CCl4 model of liver fibrosis we have
previously observed that the expression of CtsB was
confined to activated HSCs and not in parenchymal
cells,31 we cannot reach such a conclusion in the present
human cohort, which will need further study. Therefore,
the present level of analyses suggests that certain pa-
tients with histological NASH have abnormal expression
of hepatic ASMase and CtsB mRNA.
Discussion
Using in vitro HSCs and in vivo models of liver fibrosis, we
describe a previously unknown role for ASMase in HSC
activation and liver fibrosis and establish a causal rela-
tionship between ASMase and cathepsins in HSC biol-
ogy. Up-regulation of ASMase has been described in
Figure 6. ASMase/ mice display similar liver damage but decreased fibrosis after CCl4 injection. Six weeks after initial CCl4 challenge, we determined serum
ALT (A), hydroxyproline levels (B), Col1A1 mRNA expression (C), -SMA immunostaining (D), and H&E and Sirius Red staining of liver samples (E) from
ASMase/ and ASMase/ mice. Data are means  SEM; n  5 animals per group. In A, B, and C, *P  0.05 versus vehicle-treated mice. In B and C, **P 
0.05 versus ASMase/  CCl4-treated mice.
Figure 7. ASMase and CtsB expression are increased in patients with NASH.
Liver samples from control or NASH subjects were processed for RNA
isolation to determine the expression of ASMase mRNA (A) and CtsB mRNA
(B). Patients with NASH were separated in two groups: those with a score of
3 to 4 or borderline NASH, and those with a score of 5 to 6 or definite NASH,
according to the Kleiner classification. P values are indicated in the graph.
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similar contexts such as differentiation of monocytes to
macrophages42 and in drug-induced differentiation of
leukemia cells.43 Although the participation of ceramide
generated by ASMase in multiple signaling cellular pro-
cesses of physiological or pathological impact, such as
radiation-induced apoptosis,44 Wilson disease,45 fulmi-
nant hepatitis,25 cystic fibrosis,46 Pseudomonas aerugi-
nosa infection,19 or emphysema,47 and in other common
diseases27 has been reported, the role of ASMase in HSC
activation and liver fibrogenesis had not been fully char-
acterized so far. Recent observations suggest that the
activation of rat HSCs by hydrophobic bile acids is me-
diated by NAPDH oxidases in an ASMase- and protein
kinase C-dependent manner.48 However, the contribu-
tion of ASMase per se to the activation of HSCs and liver
fibrosis was not specifically addressed. Our results indi-
cate that pharmacological inhibition or silencing of
ASMase decreases the profibrogenic phenotype of
HSCs, further supporting the participation of ASMase in
HSC transdifferentiation. Moreover, the involvement of
ASMase in HSC activation and proliferation was also
validated in LX2 cells, a well established human HSC cell
line, indicating that the regulation of HSC activation by
ASMase may have potential relevance in human liver
fibrosis.
Most previous studies linked ASMase-derived cer-
amide to cell death, even though the direct targets of
ASMase-derived ceramide are still poorly defined.12 For
instance, in liver injury, ASMase activation has been
shown to promote hepatocyte apoptosis mediated by
TNF25,26 or hepatic ischemia-reperfusion33 or in Wilson’s
disease.45 Our findings add another facet of ASMase in
liver pathobiology: ASMase promotes HSC activation and
liver fibrosis by regulating CtsB/D processing. Although
cathepsins and possibly other acidic proteases partici-
pate in self-sustained processing events,31 our data in-
dicate that ASMase is essential for CtsB/D processing,
but not vice versa, suggesting that ASMase is upstream of
both CtsB and CtsD.
After the encouraging results observed with antago-
nism of ASMase by pharmacological inhibition or siRNA
silencing, we used a genetic model of ASMase defi-
ciency. Surprisingly, complete loss of ASMase activity in
the ASMase knockout mouse reflected by undetectable
activity of ASMase resulted in an enhanced basal level of
CtsB and CtsD processing (not shown) compared with
that of either wild-type or ASMase/ mice (which exhibit
a partial reduction in ASMase as shown in Figure 4A).
Because we observed that ASMase is critical for the
proteolytic processing of both CtsB and CtsD, these find-
ings with the knockout mice indicate that the total loss of
ASMase leads to a compensatory gain of function of
cathepsins, which in turn, exacerbates in vivo fibrosis
after carbon tetrachloride administration (not shown).
These observations are intriguing and merit further as-
sessment. Total loss of ASMase is pathological and
serves as a model for Niemann-Pick type A disease.
Although Niemann-Pick type A disease is mainly charac-
terized by rapid neurodegeneration, these patients also
often exhibit liver deterioration, with some patients dying
of liver failure within 3 years before the onset of the
neurological symptoms.49 Interestingly, introducing a
partially functional gene (8% residual ASMase activity)
in mice onto the complete ASMase knockout background
prevented the neurological phenotype, and the mice ex-
hibited a normal lifespan.50 Hence, these observations
provide evidence that very low levels of ASMase activity
are sufficient to eliminate the pathological state induced
by complete ASMase deficiency, illustrating the paradox-
ical role of ASMase in pathophysiology.49
In sharp contrast with the observations with ASMase
knockout mice, our data with heterozygous ASMase
clearly indicate a vital role for ASMase in the regulation of
HSC activation and proliferation in vitro as well as liver
fibrogenesis in vivo by modulating the processing of CtsB
and CtsD. Although the role of ASMase in in vivo liver
fibrosis induced by BDL and CCl4 is consistent with our in
vitro observations, the impact of ASMase on hepatocyte
Table 1. Clinical Data of Patients with Borderline or Definite NASH
Borderline NASH (n  14) Definite NASH (n  18) P
Age (years) 44.07  3.31 49.5  2.16 NS
Female (%) 42.86 66.66 NS
BMI (kg/m2) 47.56  1.94 50.49  1.86 NS
Waist circumference (cm) 142.19  4.17 138.08  5.01 NS
Diabetes (%) 35.71 50 NS
Hypertension (%) 64.28 77.77 NS
Metabolic syndrome 71.43 88.88 NS
Glucose (mg/dl) 121  12 133  13 NS
HOMA 12.82  2.82 11.93  1.55 NS
Cholesterol (mg/dl) 184.57  8.56 203.39  7.87 NS
Triglycerides (mg/dl) 137.85  11.34 147  15.68 NS
GGT (U/L) 38  4 51  9 0.047
ALT (U/L) 42  5 62  7 NS
AST (U/L) 33  3 41  4 0.002
Bilirubin (mg/dl) 0.57  0.06 0.58  0.05 NS
Platelet count (109) 296  15 297  17 NS
Fibrosis, stage 1 to 3 (%) 71 91.44 NS
Data are means  SE or %.
NS, not significant; HOMA, homeostasis model assessment; GGT, -glutamyl transferase; ALT, alanine transferase; AST, aspartate aminotransferase.
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damage caused by cholestasis is unexpected and de-
serves further comment. The extent of liver damage
caused by BDL, a model of liver injury mediated predom-
inantly by accumulation of toxic bile acids, was extensive
in wild-type mice, accompanied by inflammatory cells
infiltration, features that were markedly reduced in het-
erozygous ASMase mice. These findings point to a novel
role of ASMase in cholestasis-mediated hepatocellular
injury, which deserves further study to determine the
underlying mechanisms. Recently, Osawa et al,41 as-
sessed the specific role of ASMase in Kupffer cells during
BDL-induced cholestasis. Somewhat contrary to our ob-
servations, silencing ASMase in Kupffer cells but not in
hepatocytes impaired BDL-mediated AKT activation in
hepatocytes, which was essential for cell survival and
liver regeneration. On the other hand, deoxycholic acid
has been reported to activate c-Jun NH2-terminal kinase,
a stress-activated kinase that regulates cell death, by a
mechanism involving the ASMase/Fas receptor.51 Thus,
although it was out of the scope of the study, our obser-
vations point to a novel role for ASMase in BDL-induced
hepatocyte injury.
Paralleling the resistance of heterozygous ASMase
mice to hepatocyte damage caused by BDL, collagen
synthesis and liver fibrosis were significantly reduced, in
line with the notion that hepatocellular damage is an
important trigger of HSC activation and hence fibrosis
fostered in previous studies.52 In contrast, in the experi-
mental model of liver fibrosis by chronic CCl4 administra-
tion, heterozygous ASMase mice display liver damage
similar to that of wild-type mice but reduced fibrosis, thus
strengthening the evidence for a critical contribution of
ASMase in HSC activation, independent of hepatocellular
damage.
Overall, our findings indicate a dual function of
ASMase in liver fibrogenesis with a direct role primarily
determined by the regulation of HSC activation/prolifera-
tion via CtsB/D processing and an indirect role by mod-
ulating hepatocyte susceptibility to apoptosis induced by
cholestasis and perhaps other forms of liver injury. In
view of our findings indicating that ASMase is upstream
of CtsB in HSCs and the critical role of CtsB in BDL-
induced hepatocyte apoptosis,52 the functional relation-
ship between ASMase and CtsB in the hepatocellular
susceptibility to BDL deserves further investigation.
Given the role of ASMase in regulating hepatocellular
injury shown in previous studies25,26 and liver fibrosis in
the present study, this enzyme may be an attractive
target for chronic liver diseases. Therefore, a therapy
based on ASMase antagonism may induce a dual ben-
eficial effect, on the one hand by limiting ASMase activity
in hepatocytes and thus protecting them from hepatocel-
lular damage, and on the other hand by interfering with
HSC activation and reducing liver fibrosis.
Finally, our findings indicate that patients with NASH
exhibit increased expression of ASMase and CtsB mRNA
levels compared with healthy controls. However, we can-
not rule out the contribution of other features of NASH
apart from fibrosis, such as apoptosis, to this outcome.
Therefore, further work is needed to identify the cell pop-
ulation of enhanced CtsB and ASMase expression and
mechanisms responsible for these events in human livers
and validate whether the increase in ASMase/CtsB
mRNA occurs in liver fibrosis of different etiology such as
chronic viral hepatitis.
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